[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368666-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368666-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mirna-338-3p-influences-the-liver-cancer-stem-cells-and-lenvatinib-resistance-properties-by-targeting-sox4","miRNA-338-3p influences the liver cancer stem cells and lenvatinib resistance properties by targeting SOX4","","miR-338-3p plays a key role in hepatic cancer stem cells (CSCs) and in sensitivity to lenvatinib in hepatocellular carcinoma (HCC). miR-338-3p deficiency increases self-renewal and tumor malignancy in liver CSCs, whereas miR-338-3p overexpression suppresses tumorigenesis and self-renewal. Mechanistically, miR-338-3p specifically targets SOX4, and downregulation of SOX4 prevents tumorigenesis and self-renewal in liver CSCs. In HCC cells, miR-338-3p overexpression enhances lenvatinib-induced apoptosis and inhibits cell progression, suggesting miR-338-3p as a predictor of therapeutic benefit and an alternative candidate pathway via SOX4.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mirna-338-3p-influences-the-liver-cancer-stem-cells-and-lenvatinib-resistance-properties-by-targeting-sox4/368666/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mirna-338-3p-influences-the-liver-cancer-stem-cells-and-lenvatinib-resistance-properties-by-targeting-sox4/368666.png","ImageObject",300,407,{"name":42,"@type":43},"Terk","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What effect does miR-338-3p have on hepatic cancer stem cells?","Question",{"text":63,"@type":64},"miR-338-3p deficiency increases self-renewal and tumor malignancy in hepatic CSCs, while miR-338-3p overexpression suppresses tumorigenesis and self-renewal.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does miR-338-3p mechanistically influence liver CSC behavior?",{"text":68,"@type":64},"miR-338-3p specifically targets SOX4, and the SOX4 downregulation prevents tumorigenesis and self-renewal in liver CSCs.",{"name":70,"@type":61,"acceptedAnswer":71},"How is miR-338-3p linked to lenvatinib response in HCC?",{"text":72,"@type":64},"miR-338-3p overexpression in HCC cells responds to lenvatinib-induced apoptosis and inhibits cell progression. Patient cohort evidence suggests miR-338-3p may predict lenvatinib benefits, and SOX4 may be a therapeutic candidate through modulation of this sensitivity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368666,1790787652,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nmiRNA-338-3p influences the liver cancer stem cells and lenvatinib resistance properties by targeting SOX4  \nYing Yuan1,3, Hui-fen Li2,3􀀍, Zi-mei Liu1􀀍 & Li-ping Yu1􀀍  \nCancer stem cells (CSCs) are critical players in the pathogenesis of human-associated cancers. It is well established that the stemness ofCSCs is modulated by microRNA (miRNA) . In the current study, themiR-338-3p deficiency increased self-renewal and tumor malignancy in hepatic CSCs. Nevertheless, miR-338-3p overexpression suppresses tumorigenesis and self-renewal in liver CSCs. Mechanistically, miR-338-3p specifically targets SOX4 in liver CSCs. Moreover, miR-338-3p-associated downregulation of SOX4 prevents tumorigenesis and self-renewal in the CSCs ofthe liver. The miR-338-3poverexpression in hepatocellular carcinoma (HCC) cells was responsive to lenvatinib-induced apoptosis and cell progression inhibition. Patients’ cohort shows that miR-338-3p may predict Lenvatinib benefits in HCC patients. Furthermore, by decreasing the miR-338-3p overexpression sensitivity to Lenvatinib-induced cell death in HCC cells, SOX4 may be a potential therapeutic candidate. In conclusion, miR-338-3p has a considerable function in liver CSC self-renewal and tumor development, making it a promising therapeutic target against HCC.  \nKeywords Liver cancer stem cell, Hepatocellular carcinoma, miR-338-3p, SOX4, lenvatinib  \nAbbreviations  \nCSCs Cancer stem cells  \nHCC Hepatocellular carcinoma T-ICs Tumor-initiating cells NC Negative control  \nPDX Derive xenograft  \nThe malignancy hepatocellular carcinoma (HCC) impacts the liver. It is the sixth-primary contributor of mortalities due to cancer globally and is the most common cancer with the highest incidence1. Surgical excision is the most effective method for early diagnosis of HCC2. Surgical excision and liver transplantation offer the only hope of a cure; however, both procedures have limited utility. Moreover, most HCC patients are detected at the middle to progressive stage3. Lenvatinib is the latest approved targeted drug for treating advanced HCC4. It has been reported to be more effective than sorafenib. Many people with HCC are resistant to Lenvatinib. The negative effects for some patients with HCC can be rather severe5,6. Finding biomarkers of Lenvatinib responsiveness and understanding the mechanism of Lenvatinib resistance is paramount.  \nCSCs, or cancer stem cells, are a subset of cancer cells and have an illimitable competence for proliferation and division7,8. CSCs have been linked to controlling tumor growth, spread, relapse, and resistance to chemotherapy9–11. CSCs are the decisive factors in tumor metastasis and recurrence12, 13. The presence of hepatic CSCs has also been established by prior research14. However, the mechanism behind the spread of hepatic CSCsis still a mystery.  \nMicroRNAs (miRNAs) are non-coding RNA molecules that considerably contribute to gene regulation and are extremely tiny and highly conserved15. Multiple studies have demonstrated the significance of miRNAsin controlling several biological processes16. In certain malignancies, miRNAs function either as a tumor suppressor or an oncogene17–19. Improvements in therapeutics require a better knowledge of miRNA molecular  \n1Department of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, 1111, Xianxia Road, Shanghai 200336, China. 2Department of Hepatic Surgery & Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. 3Ying Yuan and Hui-fen Li contributed equally to this work. 􀀍 email: [huifen0823@163.com](huifen0823@163.com); [lzm890819@163.com](lzm890819@163.com); [atplx@163.com](atplx@163.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \npathways, which would shed light on the development and advancement of cancer and other disorders. Furthermore","cbCaibVXlbjus5LK","https://ap.wps.com/l/cbCaibVXlbjus5LK","pdf",1745527,"English","# Introduction\n## Cancer stem cells and microRNA regulation\n## Lenvatinib resistance and biomarker need\n# Materials and methods\n## HCC sample collection\n## Cell culture","[{\"question\":\"What effect does miR-338-3p have on hepatic cancer stem cells?\",\"answer\":\"miR-338-3p deficiency increases self-renewal and tumor malignancy in hepatic CSCs, while miR-338-3p overexpression suppresses tumorigenesis and self-renewal.\"},{\"question\":\"How does miR-338-3p mechanistically influence liver CSC behavior?\",\"answer\":\"miR-338-3p specifically targets SOX4, and the SOX4 downregulation prevents tumorigenesis and self-renewal in liver CSCs.\"},{\"question\":\"How is miR-338-3p linked to lenvatinib response in HCC?\",\"answer\":\"miR-338-3p overexpression in HCC cells responds to lenvatinib-induced apoptosis and inhibits cell progression. Patient cohort evidence suggests miR-338-3p may predict lenvatinib benefits, and SOX4 may be a therapeutic candidate through modulation of this sensitivity.\"}]","miRNA-338-3p influences the liver cancer stem cells and lenvatinib resistance properties by targeting SOX4 | PDF",1790177946,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ef94680c119b4931df1541f503984a8.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/292be21436537193a93cd53d251d6e62.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f8bb7d869b0dcbcd4e0f014fdf2099a.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a03f3785a0caca4ecb8171d1be70159.webp",980,1287]